Chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia: a narrative review

The treatment landscape for chronic lymphocytic leukemia (CLL) is changing rapidly. Novel targeted agents such as ibrutinib, venetoclax and idelalisib have made a significant impact on both first line, relapsed/refractory, and high-risk disease. Despite these advances, there are continuous needs for new treatment options, especially for patients who fail or cannot tolerate these novel therapies.In 2011, Porter et al reported the first successful use of autologous chimeric antigen receptor T-cells (CART) directed against CD19 in 3 refractory CLL patients.

Source: Clinical Lymphoma, Myeloma and Leukemia - July 20, 2017 Category: Hematology Authors: Anthony R. Mato, Meghan C. Thompson, Chadi Nabhan, Jakub Svoboda, Stephen J. Schuster Tags: Review Article Source Type: research